Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Salarius Pharmaceuticals

NASDAQ SLRX
$0.49 -0.0100 -2.00%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 13 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

1.97M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
-3.64M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.85
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
3.94M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-23.08 %

Upcoming events Salarius Pharmaceuticals

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Salarius Pharmaceuticals

Stock analysis Salarius Pharmaceuticals

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-0.16 27.58
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
0.37 3.97
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
0.28 10.54
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
0.44 0.24
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-235.71 10.75

Price change Salarius Pharmaceuticals per year

0.63$ 3.50$
Min Max

Summary analysis Salarius Pharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Salarius Pharmaceuticals

Revenue and net income Salarius Pharmaceuticals

All parameters

Stock news Salarius Pharmaceuticals

All news
11 July 2023 в 15:55

Salarius Pharmaceuticals Gets FDA Clearance for Lymphoma Drug Application

11 July 2023 в 15:55

Salarius Pharmaceuticals Gets FDA Clearance for Lymphoma Drug Application

9 May 2023 в 15:20

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

9 May 2023 в 15:15

Salarius Pharmaceuticals stock soars 31% premarket after FDA lifts partial clinical hold on Ewing sarcoma trial

22 April 2022 в 16:51

Salarius Pharmaceuticals Shares Plumb New Depths After Stock Sale >SLRX

22 April 2022 в 16:51

Salarius Pharmaceuticals Shares Plumb New Depths After Stock Sale >SLRX

About company Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and potential biomarkers for Seclidemstat (SP-2577). Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Address:
2450 Holcombe Boulevard, Houston, TX, United States, 77021
Company name: Salarius Pharmaceuticals
Issuer ticker: SLRX
ISIN: US79400X1072
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2015-01-29
Sector: Healthcare
Industry: Biotechnology
Site: https://www.salariuspharma.com

On which stock exchange are Salarius Pharmaceuticals (SLRX) stocks traded?

Salarius Pharmaceuticals (SLRX) stocks are traded on NASDAQ.

What is the ticker of Salarius Pharmaceuticals stocks (SLRX)?

The stock ticker of Salarius Pharmaceuticals’s stocks or in other words, the code is SLRX. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Salarius Pharmaceuticals (SLRX) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Salarius Pharmaceuticals (SLRX) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Salarius Pharmaceuticals (SLRX) stocks traded?

Salarius Pharmaceuticals (SLRX) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Salarius Pharmaceuticals (SLRX) stocks today?

The current price of Salarius Pharmaceuticals stocks on 14.05.2024 is 0.49 dollars. per share.

What is the dynamics of Salarius Pharmaceuticals (SLRX) stocks from the beginning of the year?

Salarius Pharmaceuticals (SLRX) quotes have increased by -23.45% from the beginning of the year up to 0.49 dollars. per 1 stocks.

How much did Salarius Pharmaceuticals (SLRX) stocks increase in мае 2024?

This month Salarius Pharmaceuticals (SLRX) quotes have increased by -8.63% to 0.49 dollars. per share.

How much are Salarius Pharmaceuticals (SLRX) stocks worth?

Today, on October, 14.05.2024 Salarius Pharmaceuticals’s (SLRX) stocks cost 0.49 dollars..

What is the market capitalization of Salarius Pharmaceuticals (SLRX)?

Capitalization is the market value of Salarius Pharmaceuticals (SLRX) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 14.05.2024, the market capitalization of Salarius Pharmaceuticals (SLRX) is estimated at about 1969216 dollars.